DK36492D0 - Praeparat - Google Patents

Praeparat

Info

Publication number
DK36492D0
DK36492D0 DK92364A DK36492A DK36492D0 DK 36492 D0 DK36492 D0 DK 36492D0 DK 92364 A DK92364 A DK 92364A DK 36492 A DK36492 A DK 36492A DK 36492 D0 DK36492 D0 DK 36492D0
Authority
DK
Denmark
Prior art keywords
preparation
Prior art date
Application number
DK92364A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK92364A priority Critical patent/DK36492D0/da
Publication of DK36492D0 publication Critical patent/DK36492D0/da
Priority to PCT/DK1993/000098 priority patent/WO1993018785A1/en
Priority to EP93907819A priority patent/EP0631504A1/en
Priority to AU38887/93A priority patent/AU3888793A/en
Priority to JP5516181A priority patent/JPH07504669A/ja
Priority to KR1019940703281A priority patent/KR950700754A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92364A 1992-03-19 1992-03-19 Praeparat DK36492D0 (da)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat
PCT/DK1993/000098 WO1993018785A1 (en) 1992-03-19 1993-03-18 Novel medicament
EP93907819A EP0631504A1 (en) 1992-03-19 1993-03-18 Novel medicament
AU38887/93A AU3888793A (en) 1992-03-19 1993-03-18 Novel medicament
JP5516181A JPH07504669A (ja) 1992-03-19 1993-03-18 新規薬剤
KR1019940703281A KR950700754A (ko) 1992-03-19 1994-09-17 신규의 약물(novel medicament)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat

Publications (1)

Publication Number Publication Date
DK36492D0 true DK36492D0 (da) 1992-03-19

Family

ID=8092684

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat

Country Status (6)

Country Link
EP (1) EP0631504A1 (da)
JP (1) JPH07504669A (da)
KR (1) KR950700754A (da)
AU (1) AU3888793A (da)
DK (1) DK36492D0 (da)
WO (1) WO1993018785A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
BR9306551A (pt) * 1992-06-15 1998-09-15 Pfizer Derivados de peptídeo do tipo glucagona e de insulinotropina
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE19530865A1 (de) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
ATE466026T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
CO5090908A1 (es) * 1998-08-28 2001-10-30 Lilly Co Eli Procedimiento para administrar peptidos insulinotropicos
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
CA2358107C (en) * 1998-12-22 2011-08-23 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
ATE309818T1 (de) 2000-03-08 2005-12-15 Novo Nordisk As Senkung des serum cholesterols
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
WO2007061434A2 (en) * 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
EP1965828A2 (en) * 2005-12-02 2008-09-10 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
EP2259802A1 (en) 2008-03-31 2010-12-15 Glaxo Group Limited Drug fusions and conjugates
US8779103B2 (en) 2009-03-27 2014-07-15 Glaxo Group Limited Drug fusions and conjugates
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2013083826A2 (en) 2011-12-09 2013-06-13 Novo Nordisk A/S Glp-1 agonists
GB201308753D0 (en) * 2013-05-15 2013-06-26 Stichting Nl Kanker Inst Compounds and their use in therapy
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
WO2023283393A2 (en) * 2021-07-08 2023-01-12 Gila Therapeutics, Inc. Methods for inducing satiety and treating metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
AU639228B2 (en) * 1989-02-17 1993-07-22 Transave, Inc. Lipid excipient for nasal delivery and topical application
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
ES2113879T3 (es) * 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.

Also Published As

Publication number Publication date
AU3888793A (en) 1993-10-21
JPH07504669A (ja) 1995-05-25
KR950700754A (ko) 1995-02-20
WO1993018785A1 (en) 1993-09-30
EP0631504A1 (en) 1995-01-04

Similar Documents

Publication Publication Date Title
DE59303358D1 (de) Quaterrylentetracarbonsäureimide
DE59306810D1 (de) Gutbettwalzenmühle
DE59302851D1 (de) Sportschuh
BR9305745A (pt) Quebra-luz
DE59301902D1 (de) Kassenlade
DE59305364D1 (de) Rotornut
BR9301712A (pt) Aplainador
DE59304139D1 (de) Polyanile
FIU920454U0 (fi) Raeddningsanordning
ATA227792A (de) Sportschuh
DE59301762D1 (de) Chlorethylsulfonylbenzaldehyde
DK59092D0 (da) Praeparat
SK964U (sk) Komplexný fytogeriatrický preparát
DE59206388D1 (de) Kabeleckkanal
BR7200318U (pt) Cabide sanfonado
ATA27393A (de) Alpinski
BR9202723A (pt) Pipex
BR9203234A (pt) Sofa-mesa
FIU920178U0 (fi) Fyllning foer WC-spolcistern
ATA58493A (de) Lochstein
BR7201352U (pt) Luninaria
FIU920437U0 (fi) Skraptramsportoer
BR9200554A (pt) Lixoduto
BR7200879U (pt) Cocho saleiro biazi
BR9204368A (pt) Auto-coletor

Legal Events

Date Code Title Description
ATS Application withdrawn